TrovaGene Licenses SF3B1 Mutations, Plans LDT | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – TrovaGene today announced it is licensing mutations of the SF3B1 splicing factor, which have been associated with disease progression and chemotherapy response in patients with chronic lymphocytic leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.